IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
DESIGN OF epsilon -POLYCAPROLACTONE NANOPARTICULATED SCAFFOLDS FOR BOSENTAN MONOHYDRATE CONTROLLED RELEASE.
Autor/es:
VIRNA MARTÍN GIMENÉZ; WALTER MANUCHA; DIEGO KASSUHA
Lugar:
Merlo
Reunión:
Jornada; XXXV Reunión Científica Anual de la Sociedad de Biología de Cuyo; 2017
Institución organizadora:
Sociedad de Biología de Cuyo
Resumen:
Electrohydrodynamic techniques refer to the dynamics of electrically charged fluids. One of its operative regimes is electrospraying, for the generation of polymeric nano and microparticles. This technique allows, to reach, a uniform dispersion of the drug within the polymer matrix achieving high encapsulation efficiency, by showing an easy operation and a good profitability. Our objective was to study the behavior of a nanostructured platform designed as scaffold of containment and prolonged/controlled drug release. Nanoparticles loaded with Bosentan monohydrate were developed by subjecting a 0.5% w/w ε-Polycaprolactone (PCL) in acetone solution to flow conditions of 0.5 ml/h and voltage of 10 kV, the drug was incorporated to the polymeric solution in a 0.8:1 (drug:PCL) ratio. The morphology and size distribution, structure, thermal and biopharmaceutical properties of these particles were determined by SEM, XRD, DSC and diffusion through dialysis bag, respectively. Heterogeneous particle sizes were observed by the SEM showing micro and nanoparticles (150 to 1150 nm) with predominance (>60%) of particles smaller than 550 nm. The obtained nanostructures presented semi crystalline properties as inferred by the XRD and DSC scanning. These properties indicate a possible interaction between the amorphous PCL and crystalline Bosentan. Additionally, in vitro assays during 24 and 72 hours showed prolonged release in biological media. As a conclusion, we demonstrate that the manufacture of these Bosentan controlled release nanoplatforms is an interesting contribution in the development of new therapeutic alternatives for the treatment of pathologies such as pulmonary hypertension and other related diseases.